Literature DB >> 32372306

The novel founder homozygous V225M mutation in the HSD17B3 gene causes aberrant splicing and XY-DSD.

Sharon Zeligson1, Eran Lavi2,3, Tehila Klopstock2,1, David Zangen4,5, Reeval Segel2,1, Floris Levy-Khademi6,7, Boris Chertin2,8, Carmit Avnon-Ziv9, Abdulsalam Abulibdeh2,3, Paul Renbaum1, Tzvia Rosen1, Shira Perlberg-Bengio1, Fouad Zahdeh1, Doron M Behar10, Ephrat Levy-Lahad2,3.   

Abstract

PURPOSE: Mutations in the gene HSD17B3 encoding the 17-beta hydroxysteroid dehydrogenase 3 enzyme cause testosterone insufficiency leading to XY disorders of sex development. In this study the clinical and molecular characteristics of three patients from consanguineous families are elucidated.
METHODS: We identified three patients from two unrelated families with XY DSD and a novel homozygous HSD17B3:c. 673G>A mutation. The effect of the mutation on splicing was determined in RNA extracted from the testis of one patient.
RESULTS: Three patients presented at ages 0.1, 8 and 0.7 years with ambiguous genitalia and an XY Karyotype. Endocrine workup showed normal cortisol and mineralocorticoid levels with a low testosterone/androstenedione ratio. Whole-exome sequencing, carried out in the first family, revealed a homozygous novel mutation in the HSD17B3 gene: c. 673G>A, p. V225M. The same mutation was found by Sanger sequencing in the third unrelated patient. Haplotype analysis of a 4 Mb region surrounding the HSD17B3 gene on chromosome 9 revealed that the mutation resides on the same allele in all three patients. The mutation, being the first nucleic acid on exon 10, affects splicing and causes exon 10 skipping in one of our patients' testes.
CONCLUSION: The novel homozygous c. 673G>A, p. V225M mutation in the 17HSDB3 gene is likely a founder mutation and causes severe XY-DSD. It changes a conserved amino acid residue, and also alters 17HSDB3 gene transcription by causing skipping of exon 10, thereby contributing to an imbalance in the relevant protein isoforms and consequently, significant decreased 17HDSB3 enzymatic activity.

Entities:  

Keywords:  17βHSD; Ambiguous genitalia; Gene transcription; Testosterone; XYDSD

Mesh:

Substances:

Year:  2020        PMID: 32372306     DOI: 10.1007/s12020-020-02327-z

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  3 in total

1.  17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations.

Authors:  A L Boehmer; A O Brinkmann; L A Sandkuijl; D J Halley; M F Niermeijer; S Andersson; F H de Jong; H Kayserili; M A de Vroede; B J Otten; C W Rouwé; B B Mendonça; C Rodrigues; H H Bode; P E de Ruiter; H A Delemarre-van de Waal; S L Drop
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

2.  Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3).

Authors:  N Moghrabi; I A Hughes; A Dunaif; S Andersson
Journal:  J Clin Endocrinol Metab       Date:  1998-08       Impact factor: 5.958

3.  Mechanisms of androgen production in male pseudohermaphroditism due to 17 beta-hydroxysteroid dehydrogenase deficiency.

Authors:  A Rösler; A Bélanger; F Labrie
Journal:  J Clin Endocrinol Metab       Date:  1992-09       Impact factor: 5.958

  3 in total
  2 in total

Review 1.  Disorder of Sex Development Due to 17-Beta-Hydroxysteroid Dehydrogenase Type 3 Deficiency: A Case Report and Review of 70 Different HSD17B3 Mutations Reported in 239 Patients.

Authors:  Catarina I Gonçalves; Josianne Carriço; Margarida Bastos; Manuel C Lemos
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

2.  Detection of 46, XY Disorder of Sex Development (DSD) Based on Plasma Cell-Free DNA and Targeted Next-Generation Sequencing.

Authors:  Luigia De Falco; Carmelo Piscopo; Rossana D'Angelo; Eloisa Evangelista; Teresa Suero; Roberto Sirica; Raffaella Ruggiero; Giovanni Savarese; Antonella Di Carlo; Giulia Furino; Ciro Scarpato; Antonio Fico
Journal:  Genes (Basel)       Date:  2021-11-25       Impact factor: 4.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.